Comparison of Ranibizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration treated following a 'Treat and Extend' protocol: efficacy variables from the pre-specified 12-month interim analysis of the RIVAL study

被引：0
|
作者：
Gillies, Mark C. [1 ]
Hunyor, Alex [1 ]
Arnold, Jennifer [2 ]
Pecheur, Francois [3 ]
Underhill, Kathryn [3 ]
Guymer, Robyn H. [4 ]
McAllister, Ian [5 ]
机构：
[1] Univ Sydney, Ophthalmol, Sydney, NSW, Australia
[2] Marsden Eye Specialists, Parramatta, NSW, Australia
[3] Novartis Pharmaceut, Sydney, NSW, Australia
[4] CERA, Sydney, NSW, Australia
[5] Lions Eye Inst, Perth, WA, Australia
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
840
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
    Gale, Richard P.
    Pearce, Ian
    Eter, Nicole
    Ghanchi, Faruque
    Holz, Frank G.
    Schmitz-Valckenberg, Steffen
    Balaskas, Konstantinos
    Burton, Ben J. L.
    Downes, Susan M.
    Eleftheriadis, Haralabos
    George, Sheena
    Gilmour, David
    Hamilton, Robin
    Lotery, Andrew J.
    Patel, Nishal
    Prakash, Priya
    Santiago, Cynthia
    Thomas, Saju
    Varma, Deepali
    Walters, Gavin
    Williams, Michael
    Wolf, Armin
    Zakri, Rosina H.
    Igwe, Franklin
    Ayan, Filis
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2020, 104 (04) : 493 - 499
  • [42] Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat-and-Extend Regimen
    Turksever, Cengiz
    Prunte, Christian
    Hatz, Katja
    OPHTHALMOLOGICA, 2017, 238 (03) : 172 - 178
  • [43] Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study
    Gillies, Mark C.
    Vuong Nguyen
    Daien, Vincent
    Arnold, Jennifer J.
    Morlet, Nigel
    Barthelmes, Daniel
    OPHTHALMOLOGY, 2016, 123 (12) : 2545 - 2553
  • [44] Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA
    Yang Y.
    Downey L.
    Mehta H.
    Mushtaq B.
    Narendran N.
    Patel N.
    Patel P.J.
    Ayan F.
    Gibson K.
    Igwe F.
    Jeffery P.
    Ophthalmology and Therapy, 2017, 6 (1) : 175 - 186
  • [45] Ranibizumab for vascularized pigment epithelium detachment in neovascular age-related macular degeneration: a retrospective analysis from the 12-month real-world TWIN study
    Caillaux, Violaine
    Oubraham, Hassiba
    Cohen, Salomon Y.
    Mimoun, Gerard
    Francais, Catherine
    Fajnkuchen, Franck
    de lahitte, Ghislaine Ducos
    Baillif, Stephanie Agnes
    Finzi, Laetitia
    Souied, Eric H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [46] Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
    V P Dave
    Eye, 2015, 29 : 1630 - 1630
  • [47] EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Subgroup Analyses From the VIEW Trials
    Wong, Tien Yin
    Cheung, Chui Ming Gemmy
    Lai, Timothy Y. Y.
    Chen, Shih-Jen
    Lee, Won Ki
    Yoon, Young Hee
    Iida, Tomohiro
    Tueckmantel, Claudia
    Sowade, Olaf
    Ogura, Yuichiro
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (03): : 537 - 547
  • [48] Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
    Raja, M. S. A.
    Saldana, M.
    Goldsmith, C.
    Burton, B. J. L.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (11) : 1543 - 1545
  • [49] Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration Results from a 12-Month Randomized Phase 2 Study: AURORA Study
    Li, Xiaoxin
    Xu, Gezhi
    Wang, Yusheng
    Xu, Xun
    Liu, Xiaoling
    Tang, Shibo
    Zhang, Feng
    Zhang, Junjun
    Tang, Luosheng
    Wu, Quan
    Luo, Delun
    Ke, Xiao
    OPHTHALMOLOGY, 2014, 121 (09) : 1740 - 1747
  • [50] A real-world evaluation of frequency of ranibizumab and aflibercept deliveries for treatment-naive patients with neovascular age-related macular degeneration: 12-month results from the French LYVE survey
    Semoun, Oudy
    Blanco-Garavito, Rocio
    Cohen, Salomon Y.
    Finzi, Laetitia
    Maurin, Camille
    Souied, Eric H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
12345